Your browser doesn't support javascript.
loading
Glucagon blockade restores functional ß-cell mass in type 1 diabetic mice and enhances function of human islets.
Wang, May-Yun; Dean, E Danielle; Quittner-Strom, Ezekiel; Zhu, Yi; Chowdhury, Kamrul H; Zhang, Zhuzhen; Zhao, Shangang; Li, Na; Ye, Reshing; Lee, Young; Zhang, Yiyi; Chen, Shiuhwei; Yu, Xinxin; Leonard, Derek C; Poffenberger, Greg; Von Deylen, Alison; McCorkle, S Kay; Schlegel, Amnon; Sloop, Kyle W; Efanov, Alexander M; Gimeno, Ruth E; Scherer, Philipp E; Powers, Alvin C; Unger, Roger H; Holland, William L.
Affiliation
  • Wang MY; Touchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.
  • Dean ED; Medical Service, Veterans Administration North Texas Health Care System, Dallas, TX 75216.
  • Quittner-Strom E; Division of Diabetes, Endocrinology and Metabolism, Vanderbilt University Medical Center, Nashville, TN 37232.
  • Zhu Y; Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN 37232.
  • Chowdhury KH; Touchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.
  • Zhang Z; Department of Nutrition and Integrative Physiology, University of Utah College of Health, Salt Lake City, UT 84112.
  • Zhao S; Touchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.
  • Li N; Diabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
  • Ye R; Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030.
  • Lee Y; Department of Nutrition and Integrative Physiology, University of Utah College of Health, Salt Lake City, UT 84112.
  • Zhang Y; Touchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.
  • Chen S; Touchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.
  • Yu X; Touchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.
  • Leonard DC; Touchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.
  • Poffenberger G; Touchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.
  • Von Deylen A; Medical Service, Veterans Administration North Texas Health Care System, Dallas, TX 75216.
  • McCorkle SK; Touchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.
  • Schlegel A; Touchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.
  • Sloop KW; Touchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.
  • Efanov AM; Medical Service, Veterans Administration North Texas Health Care System, Dallas, TX 75216.
  • Gimeno RE; Touchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549.
  • Scherer PE; Division of Diabetes, Endocrinology and Metabolism, Vanderbilt University Medical Center, Nashville, TN 37232.
  • Powers AC; Division of Diabetes, Endocrinology and Metabolism, Vanderbilt University Medical Center, Nashville, TN 37232.
  • Unger RH; Medical Service, Veterans Administration North Texas Health Care System, Dallas, TX 75216.
  • Holland WL; Department of Nutrition and Integrative Physiology, University of Utah College of Health, Salt Lake City, UT 84112.
Proc Natl Acad Sci U S A ; 118(9)2021 03 02.
Article in En | MEDLINE | ID: mdl-33619103
ABSTRACT
We evaluated the potential for a monoclonal antibody antagonist of the glucagon receptor (Ab-4) to maintain glucose homeostasis in type 1 diabetic rodents. We noted durable and sustained improvements in glycemia which persist long after treatment withdrawal. Ab-4 promoted ß-cell survival and enhanced the recovery of insulin+ islet mass with concomitant increases in circulating insulin and C peptide. In PANIC-ATTAC mice, an inducible model of ß-cell apoptosis which allows for robust assessment of ß-cell regeneration following caspase-8-induced diabetes, Ab-4 drove a 6.7-fold increase in ß-cell mass. Lineage tracing suggests that this restoration of functional insulin-producing cells was at least partially driven by α-cell-to-ß-cell conversion. Following hyperglycemic onset in nonobese diabetic (NOD) mice, Ab-4 treatment promoted improvements in C-peptide levels and insulin+ islet mass was dramatically increased. Lastly, diabetic mice receiving human islet xenografts showed stable improvements in glycemic control and increased human insulin secretion.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Glucagon / Diabetes Mellitus, Experimental / Glucagon-Secreting Cells / Insulin-Secreting Cells / Hypoglycemic Agents / Antibodies, Monoclonal Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Proc Natl Acad Sci U S A Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Glucagon / Diabetes Mellitus, Experimental / Glucagon-Secreting Cells / Insulin-Secreting Cells / Hypoglycemic Agents / Antibodies, Monoclonal Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Proc Natl Acad Sci U S A Year: 2021 Document type: Article